Thursday, 1 Dec 2016

Noon – 1:00 PM: Registration & Working Lunch

1:00 – 2:40 PM: Session 1: Clinical Research in JMML
Moderator: Mignon Loh, MD, UCSF Benioff Childrens Hospital
1:00 – 1:20 PM ● Alice Bertaina, Ospedale Bambino Gesu
“Identification of deregulated microRNAs in Juvenile Myelomonocytic Leukemia (JMML)”
1:20 – 1:40 PM ● Wenyu Yang, Diagnostic and Therapeutic Center of Children’s Blood Diseases
“The clinical characteristics and prognosis of Juvenile myelomonocytic leukemia in single institute from China”
1:40 – 2:00 PM ● Charlotte Niemeyer, University of Freiburg
“Second HSCT in JMML”
2:00 – 2:20 PM ● Sarah Tasian, Children’s Hospital of Philadelphia
2:20 – 2:40 PM ● Tariq Arshad, KaloBios Pharmaceuticals
“Potential Use of KB003/Lenzilumab in JMML”

2:40 – 3:00 PM: Coffee Break

3:00 – 4:20 PM: Session 2: Risk Stratification for Patients Presenting with JMML
Moderators: Katherine Calvo and Elliot Stieglitz
3:00 – 3:20 PM ● Vollter Anastas, BS, Tufts University
“Whole Exome Sequencing Suggests Indolent Phenotype of RAS-Associated Autoimmune Leukoproliferative Disorder (RALD) is Characterized by Single Somatic Mutations in RAS Genes with Absence of Cooperating Mutations”
3:20 – 3:40 PM ● Hideki Muramatsu, Nagoya University
“Comprehensive genetic analysis in cases of juvenile myelomonocytic leukemia for prognostic estimation”
3:40 – 4:00 PM ● Mario Cazzola, University of Pavia
“Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia”
4:00 – 4:20 PM ● Elliot Stieglitz, University of CA, SF

4:20 – 5:20 PM: Session 3: Update on Clinical Trials
Moderator: Charlotte Niemeyer, MD, University of Freiburg
4:20 – 4:40 PM ● John Ceremsak, University of CA, SF
“A Phase II Randomization of Conditioning Regimens in Juvenile Myelomonocytic Leukemia: Results from Children’s Oncology Group Trial ASCT1221”
4:40 – 5:00 PM ● Elliot Stieglitz, University of CA, SF
“MEK Inhibition in JMML using Trametinib (ADVL 1521)”
5:00 – 5:20 PM ● Charlotte Niemeyer, University of Freiburg
“Celgene-Sponsored Trial: Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)”

6:30 - 8:00 PM: Dinner at Chianti (http://www.chiantirestaurantsd.com/) for meeting attendees and friends (self-pay)
Friday, 2 Dec 2016

8:00 – 9:00 AM: Working Breakfast

8:30 – 9:30 AM: Keynote Address:
Kevan Shokat, Ph.D.
Professor and Chair, Dept. of Cellular & Molecular Pharmacology, UCSF
Professor, Dept. of Chemistry, UC Berkeley
Investigator, Howard Hughes Medical Institute

9:30 – 10:15 AM: Session 4-1: Pre-Clinical Models and Genetics in JMML
Moderator: Rebecca Chan, Indiana University School of Medicine

9:30 – 9:45 AM
●Lucy Liu, University of Arkansas
“An Age Specific Murine Model For Juvenile Myelomonocytic Leukemia (JMML)”

9:45 – 10:00 AM
●Gen-Sheng Feng, UC San Diego
“Shp2 and Pten in leukemia and anemia”

10:00 – 10:15 AM
●Lisa Deng, Indiana University
“Evaluation of Bruton’s Tyrosine Kinase and PI3K p110δ in Mutant Shp2-Induced Juvenile Myelomonocytic Leukemia”

10:15 – 10:30 AM: Coffee Break

10:30 – 11:30 AM: Session 4-2: Pre-Clinical Models and Genetics in JMML
Moderator: Rebecca Chan, Indiana University School of Medicine

10:30 – 10:45 AM
●Lu Liu, University of Michigan
“N-RasG12D-mediated dysregulation of IRE1alpha-Xbp1s signaling promotes pre-leukemic hematopoietic stem cell expansion”

10:45 – 11:00 AM
●Stefan Tarnawsky, Indiana University
“In Utero Expression Of Kras G12D Leads To A Rapidly Fatal Myeloid Disease In Mice”

11:00 – 11:15 AM
●Elisa Dorantes, Boston Children’s Hospital
“RUNX1 is a Candidate Transcriptional Effector in Juvenile Myelomonocytic Leukemia”

11:15 – 11:30 AM
●Feng-Chun Yang, University of Miami
“Role of ASXL1 in normal hematopoiesis and pathogenesis of myeloid malignancies”

11:30 – 12:30 PM: Lunch
Update on JMML Roadmap & Proposed topics for 2017 JMML meeting
Adjournment